ALYSSA CZUDEK: Open Payments
NPI 1912552027 · ALEXANDRIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,414 in 144 payments from 19 companies in 2025. Trend: 2023 $1,707 · 2024 $1,961 · 2025 $2,414
Food & beverage: $2,414
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 15 | $296 |
| Neurocrine BioSciences, Inc. | 23 | $251 |
| ABBVIE INC. | 16 | $234 |
| Alkermes, Inc. | 13 | $225 |
| Corium, LLC | 12 | $199 |
| Tris Pharma Inc | 9 | $172 |
| Otsuka America Pharmaceutical, Inc. | 12 | $170 |
| Noven Therapeutics, LLC | 8 | $160 |
| Janssen Pharmaceuticals, Inc | 8 | $157 |
| E.R. Squibb & Sons, L.L.C. | 3 | $81 |
Products named: Auvelity, INGREZZA, VRAYLAR, ARISTADA, Azstarys, REXULTI, Dyanavel XR, Xelstrym.
Industry payments across LA — which companies pay providers there.
